These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 21333408)
21. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists. Poulsen SA; Quinn RJ J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792 [TBL] [Abstract][Full Text] [Related]
22. Discovery of highly potent and selective type I B-Raf kinase inhibitors. Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649 [TBL] [Abstract][Full Text] [Related]
23. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. Riemer C; Borroni E; Levet-Trafit B; Martin JR; Poli S; Porter RH; Bös M J Med Chem; 2003 Mar; 46(7):1273-6. PubMed ID: 12646038 [TBL] [Abstract][Full Text] [Related]
24. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies. Da Settimo F; Primofiore G; La Motta C; Taliani S; Simorini F; Marini AM; Mugnaini L; Lavecchia A; Novellino E; Tuscano D; Martini C J Med Chem; 2005 Aug; 48(16):5162-74. PubMed ID: 16078836 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity. Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651 [TBL] [Abstract][Full Text] [Related]
27. Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment. Devegowda VN; Hong JR; Cho S; Lim EJ; Choo H; Keum G; Rhim H; Nam G Bioorg Med Chem Lett; 2013 Aug; 23(16):4696-700. PubMed ID: 23820387 [TBL] [Abstract][Full Text] [Related]
29. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136 [TBL] [Abstract][Full Text] [Related]
30. Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. de la Fuente T; Martín-Fontecha M; Sallander J; Benhamú B; Campillo M; Medina RA; Pellissier LP; Claeysen S; Dumuis A; Pardo L; López-Rodríguez ML J Med Chem; 2010 Feb; 53(3):1357-69. PubMed ID: 20078106 [TBL] [Abstract][Full Text] [Related]
31. Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists. Cheong SL; Federico S; Venkatesan G; Paira P; Shao YM; Spalluto G; Yap CW; Pastorin G Bioorg Med Chem Lett; 2011 May; 21(10):2898-905. PubMed ID: 21511471 [TBL] [Abstract][Full Text] [Related]
32. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. Müller CE; Geis U; Grahner B; Lanzner W; Eger K J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445 [TBL] [Abstract][Full Text] [Related]
33. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
34. Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket. van Loevezijn A; Venhorst J; Iwema Bakker WI; Lange JHM; de Looff W; Henzen R; de Vries J; van de Woestijne RP; den Hartog AP; Verhoog S; van der Neut MAW; de Bruin NMWJ; Kruse CG Bioorg Med Chem Lett; 2016 Mar; 26(6):1605-1611. PubMed ID: 26876931 [TBL] [Abstract][Full Text] [Related]